Bio News
Expedition Therapeutics has raised $11.5 million (approximately 163.5 billion won) in a Series B financing. The company will use the funds to conduct a phase 2 trial of EXPD-101, a treatment for chronic obstructive pulmonary disease (COPD). Expedition plans to obtain initial global phase 2 data for the drug, a DPP1 inhibitor, in 2028.
Biobook Team
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
